The objective of the study is to evaluate the sensitivity of the new criteria for the classification of systemic lupus erythematosus (SLE), when applied to real SLE cases. We retrospectively reviewed the electronic medical records of 100 consecutive patients who visited St. Luke’s International Hospital. Patients were included if they were clinically diagnosed as having SLE and excluded if they had other autoimmune disease or if they were less than 18 years old. Each patient was evaluated if they satisfied the American College of Rheumatology (ACR) 1997 classification criteria (1997 criteria), 2012 Systemic Lupus International Collaborating Clinics criteria (2012 criteria), or 2019 ACR/European League Against Rheumatism (EULAR) criteria. Among the 100 patients, the sensitivity of the 1997, 2012, and 2019 criteria was, 97, 99, and 92%, respectively. The total patient score with the 2019 criteria ranged from 12 to 44 (mean, 27.3). All patients who were classified as non-SLE with the 2019 criteria had an anti-nuclear antibody (ANA) titre of < 1:80. The 2019 criteria for SLE accomplished modestly high sensitivity in the real-world practice, but not as high as the 1997 and 2012 criteria. They possibly misclassify the real SLE cases as non-SLE, especially if patients have a low titre (< 1:80) of ANA.
• The 2019 criteria for the classification of SLE achieve modestly high sensitivity in real-world practice.
• The entry criteria (ANA ≥ 1:80) possibly misclassify the real SLE cases as non-SLE, as the sensitivity of IIF-ANA in SLE varies widely depending on the staining kit.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725–1725
Petri M, Orbai A-M, Alarcón GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686. https://doi.org/10.1002/art.34473
Inês L, Silva C, Galindo M et al (2015) Classification of systemic lupus erythematosus: systemic lupus international collaborating clinics versus American College of Rheumatology Criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthritis Care Res 67(8):1180–1185. https://doi.org/10.1002/acr.22539
Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 320. https://doi.org/10.1136/annrheumdis-2018-214819
Wallace DJ, Hahn BH (2012) Dubois’ lupus erythematosus and related syndromes 8th edition, section IV, chapter 22 “overview and clinical presentation”, table 22-1. “Cumulative incidence of SLE manifestations”. Saunders, St. Louis
Leuchten N, Hoyer A, Brinks R, et al. (2018) Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data. Arthritis Care Res. \(3):428-438. doi:https://doi.org/10.1002/acr.23292
Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH (2018) Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. Ann Rheum Dis 77(6). https://doi.org/10.1136/annrheumdis-2017-212599
Hayashi N, Saegusa J, Uto K et al (2016) Evaluation of a computer-aided microscope system and its anti-nuclear antibody test kit for indirect immunofluorescence assay. Rinsho Byori 64(2):142–151
Bossuyt X, Fieuws S (2014) Detection of antinuclear antibodies: added value of solid phase assay? Ann Rheum Dis 73(3):e10. https://doi.org/10.1136/annrheumdis-2013-204793
Pregnolato F, Borghi MO, Meroni PL, Forum Interdisciplinare per la Ricerca sulle Malattie Autoimmuni (FIRMA) Study Group (2019) Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. Ann Rheum Dis 78(6):e50. https://doi.org/10.1136/annrheumdis-2018-213516
Kidd K, Cusi K, Mueller R, Goodner M, Boyes B, Hoy E (2005) Detection and identification of significant ANAs in previously determined ANA negative samples. Clin Lab 51(9–10):517–521
Chi H, Teng J, Wang Z et al (2019) Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients? Ann Rheum Dis 0:1. https://doi.org/10.1136/annrheumdis-2019-216253
Assan F, Seror R, Mariette X et al (2019) New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS. Ann Rheum Dis 0:1–2. https://doi.org/10.1136/annrheumdis-2019-216222
The authors would like to thank Hideki Nakajima for providing technical support and Editage (www.editage.com) for English language editing.
The authors received no financial support for the research, authorship, and/or publication of this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Suda, M., Kishimoto, M., Ohde, S. et al. Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients: a real-world setting analysis. Clin Rheumatol (2020). https://doi.org/10.1007/s10067-019-04848-z
- Anti-nuclear antibody
- Classification criteria
- Systemic lupus erythematosus